Interoperability, Reimbursement, and Diabetes Devices: An Interview with JDRF’s Cynthia Rice

article image

Cynthia Rice is chief mission strategy officer for JDRF, which is the leading global advocate for treatments and a cure for type 1 diabetes. She recently spoke to Market Pathways about important FDA developments in the push toward diabetes devices that can be used together seamlessly no matter the manufacturer, and she spotlighted reimbursement challenges these devices are facing.

Diabetes devices are treading new regulatory ground with recent approvals of interoperable devices—the Dexcom G6 continuous glucose monitor (Dexcom Inc.) and the t:Slim X2 (Tandem Diabetes Care)—and a submission in the works for an interoperable algorithm from health-tech non-profit start-up Tidepool.

JDRF’s Cynthia Rice discusses the interoperability efforts, as well as reimbursement challenges in the space with MTS Market Pathways.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to Market Pathways:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to Market Pathways
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: